Evaluation of the Reproducibility of the Automated Measurement of the Extent of ILD on Chest CT

NCT06743022 | Recruiting

• 2 other identifiers: APHP2407832024-A01384-43
• Study Type: interventional
• Target: 150
• Locations: 1 country
• Sites: 6

Brief Summary

In interstitial lung disease (ILD), the extent of ILD on chest computed tomography (CT) is recognized as an important prognostic factor. Automated tools are now available to quantify ILD, but there is a lack of data on the reproducibility of this measurement and therefore its accuracy. Therefore, the purpose of this study is to evaluate the variability of automated ILD quantification on chest CT. Reproducibility will be assessed by repeating chest CT scans and using different tools to measure the extent of disease.

Conditions

Interstitial Lung Disease

Keywords

Lung Diseases; Interstitial Lung Disease; Multidetector Computed Tomography; Deep Learning

Outcome Measures

Primary Outcomes (1)

• Automated Interstitial Lung Disease (ILD) quantification

  Reproducibility of ILD quantification on chest CT (as a percentage of lung volume) between two successive scan acquisitions.

  Day of inclusion

Secondary Outcomes (3)

• Automated Interstitial Lung Disease (ILD) quantification

  Day of inclusion

• Lung volume

  Day of inclusion

• Automated Interstitial Lung Disease (ILD) quantification

  Day of inclusion

Study Arms (1)

Patients with interstitial lung disease

EXPERIMENTAL

Diagnostic Test: Chest CT

Interventions

Chest CT DIAGNOSTIC_TEST

Repeated chest CT for automated ILD quantification

Patients with interstitial lung disease

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years
• Known interstitial lung disease as part of idiopathic pulmonary fibrosis or connective tissue disease
• Followed in one of the participating hospitals
• Requiring a chest CT as part of a scheduled assessment
• Affiliated to a French national social security
• Informed consent

You may not qualify if:

• Acute exacerbation of ILD
• Pregnancy
• Inability to hold an apnea for 10 seconds
• Need for additional procubitus or expiratory images

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead
• URC-CIC Paris Descartes Necker Cochin: collaborator

Study Sites (6)

APHP - Bichat hospital - Radiology

Paris, IDF, 75010, France

RECRUITING

APHP - Bichat hospital - Rheumatology

Paris, IDF, 75010, France

RECRUITING

APHP - Cochin Hospital - Internal medicine

Paris, IDF, 75014, France

RECRUITING

APHP - Cochin Hospital - Pneumology

Paris, IDF, 75014, France

RECRUITING

APHP - Cochin Hospital - Radiology

Paris, IDF, 75014, France

RECRUITING

APHP - Bichat Hospital - Pneumology

Paris, IDF, 75018, France

RECRUITING

MeSH Terms

Conditions

Lung Diseases, Interstitial; Lung Diseases

Condition Hierarchy (Ancestors)

Respiratory Tract Diseases

Study Officials

• Guillaume CHASSAGNON, MD, PhD

  Cochin Hospital - AP-HP

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Guillaume CHASSAGNON, MD, PhD

CONTACT

+33158414326; guillaume.chassagnon@aphp.fr

Marie BENHAMMANI-GODARD

CONTACT

0033158411190; marie.godard@aphp.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 16, 2024
• First Posted: December 19, 2024
• Study Start: June 24, 2025
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): September 1, 2026
• Last Updated: January 2, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

FR (6)